Immunogen (IMGN) is a biotechnology focused on developing antibody drug conjugate (ADC) immunotherapies for improving treatment of cancer. IMGN scientists have specialized expertise in target selection, including assessment of appropriate levels on tumor vs. normal tissue and rate of internalization. This makes ADC technology potentially superior to classic chemotherapies. The company outlicensed marketing approval for Kadcyla, indicated for use in treatment of second line Her+ breast cancer. Mirvertuximab soravtansine is in late-stage development for treatment of ovarian cancer, Coltuximab ravtansine in B-cell malignancies, and Isatuximab is in late clinical stage development for treatment of multiple myeloma. It has an impressive profile of clinical studies currently ongoing. The company stock is up about 100% over the past year, with a significant rise coming after releasing ASCO abstracts in May 2017 regarding its work in ovarian cancer. IMGN pipeline from the website includes a growing early-stage list of candidates with some promise and nice partnerships. The market for ovarian cancer is expected to quadruple by 2025 to $5.2 billion, with nearly $10 billion expected for Her+ breast cancer, according to globaldata.
